Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: A European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 2089-2101

  Berg, Jenny ^a,d   Fidan, Dogan ^b   Lindgren, Peter ^a,c  

^a i3 Innovus   (Sweden)

^b SANOFI   (France)

^c KAROLINSKA INSTITUTE   (Sweden)

^d House D ^*  (Sweden)

Author keywords

Clopidogrel; Cost effectiveness; Decision model; Europe; Meta analysis; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; FOLLOW UP; FRANCE; GERMANY; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL PATIENT; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROBABILITY; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; REGISTER; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; SWEDEN; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; EUROPE; HUMANS; MARKOV CHAINS; META-ANALYSIS AS TOPIC; MIDDLE AGED; MODELS, STATISTICAL; PLATELET AGGREGATION INHIBITORS; RISK; TICLOPIDINE;

EID: 47949092342     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802222261     Document Type: Article

References (35)

1. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
2. Steinhubl SR, Berger PB, Mann JT, 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
3. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-32
4. Lindgren P, Stenestrand U, Malmberg K, et al. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther 2005;27:100-10
5. Ringborg A, Lindgren P, Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ 2005;6:354-6, 8-62
6. Detsky AS, Naglie G, Krahn MD, et al. Primer on medical decision analysis: Part 2 - Building a tree. Med Decis Making 1997;17:126-35
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38
8. Hospital Discharge Register and Cause of Death Register. Swedish National Board of Health and Welfare; 1995-2003
9. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502
10. Systematic Reviews in Health Care: Meta-analysis in Context, 2nd edn. London: BMJ Publishing Group, 2001
11. Zethraeus N, Molin T, Henriksson P, et al. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999;246:151-9
12. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003;21:651-9
13. Rossnagel K, Nolte CH, Muller-Nordhorn J, et al. Medical resource use and costs of health care after acute stroke in Germany. Eur J Neurol 2005;12:862-8
14. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 1995;7:242-50
15. Bruggenjurgen B, Rupprecht H-J, Willich SN, et al. Cost of atherothrombotic diseases - myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease - in Germany. J Public Health 2005;13:216-24
16. Kolominsky-Rabas PL, Heuschmann PU, et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006;37:1179-83
17. Spieler JF, Lanoe JL, Amarenco P. Costs of stroke care according to handicap levels and stroke subtypes. Cerebrovasc Dis 2004;17:134-42
18. Drummond M, Sculpher M, Torrance G. Methods for the economic evaluation of health care programmes, 3rd Oxford: Oxford University Press; 2005
19. General guidelines for economic evaluations from the Pharmaceutical Benefits Board 2003 [cited LFNAR 2003:2; Available from: http://www.lfn.se/ LFNTemplates/Page_442.aspx
20. Burstrom K, Johannesson M, Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 2001;55:51-69
21. Lindgren P, Graff J, Olsson AG, et al. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 2007;28:1448-53
22. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64
23. Ekman M. Consumption and Production by Age in Sweden: Basic Facts and Health Economic Implications. Studies in Health Economics Modelling and Data Analysis of Costs and Survival Dissertation. For the degree of Doctor of Philosophy at the Stockholm School of Economics. Stockholm: EFI; 2002
24. Human Mortality Database. 2003 6 Feb 2007 [cited 6 February 2007]; Available from: www.mortality.org
25. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000;9:623-30
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
27. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-72
28. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28
29. Socialstyrelsens riktlinjer för hjärtsjukvård. Beslutsstöd för prioriteringar. Swedish National Board of Health and Welfare, 2004
30. Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998;98:1860-8
31. Singh M, Reeder GS, Jacobsen SJ, et al. Scores for post-myocardial infarction risk stratification in the community. Circulation 2002;106:2309-14
32. Fitchett D. The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. Can J Cardiol 2007;23:663-71
33. FASS. 2006 February 2007 [cited 6 February 2007]; Available from: www.fass.se
34. Gelbe Liste Pharmindex. 2006 6 February 2007 [cited 6 February 2007]; Available from: http://www.gelbe-liste.de/01_start/index.html
35. Kostnad per patient databasen. 2006 [cited 6 February 2007]; Available from: http://www.skl.se/bunt.asp?C=1334